I am a patient or caregiver

Please click here for Palforzia.com

I am a U.S. healthcare professional

This website is intended for U.S. healthcare professionals only. To enable certain features and improve your experience with us, this website requires cookies to be stored on your computer. To find out more about the cookies we use, please see our Privacy Notice. Please confirm you are a U.S. healthcare professional to proceed. By choosing this option, you are accepting our cookie policy.

The information in this webpage is intended for US healthcare professionals only.

For children and patients ages 1 through 17 years1

Early intervention could transform their tomorrow

building protection from allergic reactions, including anaphylaxis1


PALFORZIA®: the first and only FDA-approved oral immunotherapy (OIT) treatment for children with peanut allergy.1

LEARN ABOUT PALFORZIA

The patient images are AI generated and are not real patients treated with PALFORZIA.
Individual results will vary with each patient.

Just half a kernel of peanut*† can put a peanut-allergic patient at risk1–4

PALFORZIA has been clinically proven to reduce the severity of allergic reactions, including life-threatening anaphylaxis, that may occur with accidental exposure to peanut.1

Explore the safety and efficacy of PALFORZIA.

POSEIDON (AGES 1–3 YEARS)PALISADE (AGES 4–17 YEARS)SAFETY PROFILE


*The median amount of peanut protein that causes a reaction during accidental exposure is less than half a peanut kernel.2
†One peanut kernel is equivalent to approximately 300 mg.3

Determining if PALFORZIA is right
for your patients

Select each patient to learn more about the possible patient types in your
practice that may benefit from PALFORZIA.

Illustrative image

Meet Aaron‡

Aged 2 years

Aspiring adventurer
Illustrative image

Meet Oliver‡

Aged 6 years

Hopeful student, severely allergic
Illustrative image

Meet Anna‡

Aged 11 years

Budding athlete
Illustrative image

Meet Lucy‡

Aged 15 years

Independence seeker



‡The patients portrayed and their associated data are fictional, hypothetical and they have not
actually been treated with PALFORZIA. Individual results will vary with each patient.

PALFORZIA: Crafted precisely for
consistent dosing

Learn about the three-step dosing protocol, including additional guidance for in-
clinic and at-home dosing, and the specific manufacturing specifications for
PALFORZIA.

EXPLORE HERE

Not actual size

Preparing to prescribe PALFORZIA

Learn more about getting your practice started with
PALFORZIA treatment.

START NOW

The patient images are AI generated and are not real
patients treated with PALFORZIA. Individual results will
vary with each patient.

Illustrative image Illustrative image

Support to help patients access PALFORZIA

Explore how we can help your eligible patients with
access, coverage, and reimbursement support or
questions.

VIEW RESOURCES

Model for illustrative purposes only.

Illustrative image Illustrative image

References:  

  1. PALFORZIA [package insert]. Lenoir, NC: Greer Laboratories, Inc.
  2. Deschildre A, et al. Clin Exp Allergy. 2015;46:610–620.
  3. Vickery BP, et al. NEJM. 2018;379:1991–2001.
  4. Vickery BP, et al. J Allergy Clin Immunol Pract. 2021; 9:1879–1889.e14.

Important Safety
Information

WARNING: ANAPHYLAXIS

  • PALFORZIA can cause anaphylaxis, which may be life-threatening and can occur at any time during PALFORZIA therapy. 
  • Prescribe injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. 
  • Do not administer PALFORZIA to patients with uncontrolled asthma. 
  • Dose modifications may be necessary following an anaphylactic reaction. 
  • Observe patients during and after administration of the Initial Dose Escalation and the first dose of each Up-Dosing level, for at least 60 minutes. 
  • PALFORZIA is available only through a restricted program called the PALFORZIA REMS.

INDICATION

PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. 

PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 1 through 17 years. Up-Dosing and Maintenance may be continued in patients 1 years of age and older. 

PALFORZIA is to be used in conjunction with a peanut-avoidant diet. 

Limitation of Use: Not indicated for the emergency treatment of allergic reactions, including anaphylaxis. 

CONTRAINDICATIONS

PALFORZIA is contraindicated in patients with uncontrolled asthma, or with a history of eosinophilic esophagitis and other eosinophilic gastrointestinal disease. 

WARNINGS AND PRECAUTIONS 

ANAPHYLAXIS 

PALFORZIA can cause anaphylaxis, which may be life-threatening. PALFORZIA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the PALFORZIA REMS because of the risk of anaphylaxis. Only prescribers, healthcare settings, pharmacies, and patients certified and enrolled in the REMS Program can prescribe, receive, dispense or administer PALFORZIA. 

Anaphylaxis has been reported during all phases of PALFORZIA dosing, including Maintenance and in subjects who have undergone recommended Up-Dosing and dose modification procedures. 

Do not initiate PALFORZIA treatment in a patient who has had severe or life-threatening anaphylaxis within the previous 60 days. PALFORZIA may not be suitable for patients with certain medical conditions that may reduce the ability to survive anaphylaxis, including but not limited to markedly compromised lung function, severe mast cell disorder, or cardiovascular disease. In addition, PALFORZIA may not be suitable for patients taking medications that can inhibit or potentiate the effects of epinephrine. 

All Initial Dose Escalation doses and the first dose of each Up-Dosing level must be administered under observation in a certified health care setting. 

Patients may be more likely to experience allergic reactions following PALFORZIA administration in the presence of cofactors such as exercise, hot water exposure, intercurrent illness (e.g., viral infection), or fasting. Other potential cofactors may include menstruation, sleep deprivation, nonsteroidal anti-inflammatory drug use, or uncontrolled asthma. Patients should be proactively counseled about the potential for the increased risk of anaphylaxis in the presence of these cofactors. If possible, adjust the time of dosing to avoid these cofactors. If it is not possible to avoid these cofactors, consider withholding PALFORZIA temporarily. 

ASTHMA

Uncontrolled asthma is a risk factor for a serious outcome, including death, in anaphylaxis. Ensure patients with asthma have their asthma under control prior to initiation of PALFORZIA. 

PALFORZIA should be temporarily withheld if the patient is experiencing an acute asthma exacerbation. Following resolution of the exacerbation, resumption of PALFORZIA should be undertaken cautiously. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of PALFORZIA.

EOSINOPHILIC GASTROINTESTINAL DISEASE

Discontinue PALFORZIA and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastrointestinal symptoms, including dysphagia, vomiting, nausea, gastroesophageal reflux, chest pain, or abdominal pain.

GASTROINTESTINAL ADVERSE REACTIONS

Gastrointestinal adverse reactions were commonly reported in PALFORZIA-treated subjects, and dose modification should be considered for patients who report these reactions. For severe or persistent gastrointestinal symptoms consider a diagnosis of eosinophilic esophagitis. 

ADVERSE REACTIONS

The most common adverse reactions reported in subjects ages 1 through 3 years treated with PALFORZIA (incidence ≥5%) are cough, sneezing, rhinitis, nasal congestion, throat irritation, wheezing, abdominal pain, vomiting, diarrhea, oral pruritus, oropharyngeal pain, urticaria, rash, pruritus, and perioral dermatitis. 

The most common adverse events reported in subjects ages 4 through 17 years treated with PALFORZIA (incidence ≥ 5% and at least 5% greater than placebo) are abdominal pain, vomiting, nausea, oral pruritus, oral paresthesia, throat irritation, cough, rhinorrhea, sneezing, throat tightness, wheezing, dyspnea, pruritus, urticaria, anaphylactic reaction, and ear pruritus. 

Please see full Prescribing Information, including Boxed WARNING and Medication Guide.